R. Macaulay

1.2k total citations
71 papers, 863 citations indexed

About

R. Macaulay is a scholar working on Economics and Econometrics, Physiology and Immunology. According to data from OpenAlex, R. Macaulay has authored 71 papers receiving a total of 863 indexed citations (citations by other indexed papers that have themselves been cited), including 54 papers in Economics and Econometrics, 21 papers in Physiology and 15 papers in Immunology. Recurrent topics in R. Macaulay's work include Health Systems, Economic Evaluations, Quality of Life (52 papers), Pharmaceutical Economics and Policy (40 papers) and Biomedical Ethics and Regulation (18 papers). R. Macaulay is often cited by papers focused on Health Systems, Economic Evaluations, Quality of Life (52 papers), Pharmaceutical Economics and Policy (40 papers) and Biomedical Ethics and Regulation (18 papers). R. Macaulay collaborates with scholars based in United Kingdom, United States and Italy. R. Macaulay's co-authors include Siân M. Henson, Arne N. Akbar, Natalie E. Riddell, Valentina Libri, Maria V. D. Soares, Rita I Azevedo, Sarah Jackson, Stephen Griffiths, Ornella Franzese and Luca Battistini and has published in prestigious journals such as Blood, The Journal of Immunology and European Journal of Immunology.

In The Last Decade

R. Macaulay

60 papers receiving 845 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
R. Macaulay United Kingdom	10	517	259	177	138	110	71	863
Graham Pawelec Germany	9	472 0.9×	222 0.9×	175 1.0×	105 0.8×	134 1.2×	15	772
Carmen Campos Spain	14	671 1.3×	297 1.1×	119 0.7×	160 1.2×	148 1.3×	18	1.1k
Ho-Kee Yum South Korea	13	163 0.3×	79 0.3×	50 0.3×	63 0.5×	138 1.3×	32	555
Corona Alonso Spain	17	1.0k 1.9×	355 1.4×	113 0.6×	300 2.2×	155 1.4×	29	1.5k
Norio Yokose Japan	14	299 0.6×	72 0.3×	48 0.3×	122 0.9×	90 0.8×	37	787
Nelson López-Sejas Spain	11	485 0.9×	153 0.6×	47 0.3×	224 1.6×	80 0.7×	15	741
Fakhri Hassouneh Spain	14	532 1.0×	188 0.7×	48 0.3×	213 1.5×	86 0.8×	20	810
Victorien M. Wolters Netherlands	20	254 0.5×	478 1.8×	37 0.2×	26 0.2×	116 1.1×	44	1.1k
Suchitra Pandey United States	10	561 1.1×	132 0.5×	62 0.4×	143 1.0×	85 0.8×	28	1.2k
Elaine Huang Australia	5	778 1.5×	179 0.7×	57 0.3×	228 1.7×	97 0.9×	7	1.1k

Countries citing papers authored by R. Macaulay

Since Specialization

Citations

This map shows the geographic impact of R. Macaulay's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by R. Macaulay with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites R. Macaulay more than expected).

Fields of papers citing papers by R. Macaulay

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by R. Macaulay. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by R. Macaulay. The network helps show where R. Macaulay may publish in the future.

Co-authorship network of co-authors of R. Macaulay

This figure shows the co-authorship network connecting the top 25 collaborators of R. Macaulay. A scholar is included among the top collaborators of R. Macaulay based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with R. Macaulay. R. Macaulay is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Macaulay, R., et al.. (2024). PD169 Is China Embracing Innovation? An Analysis Of Early Access In The Boao Lecheng International Medical Pilot Zone. International Journal of Technology Assessment in Health Care. 40(S1). S157–S157. 1 indexed citations

Macaulay, R., et al.. (2023). HPR32 Is NRDL Supporting Access or Hindering Access in China? A Time-Trend Analysis From 2017-2022. Value in Health. 26(12). S259–S259. 1 indexed citations

Macaulay, R., et al.. (2023). HTA5 An Evaluation of the NICE Early Value Assessment: What Is the Opportunity for Digital Therapeutics?. Value in Health. 26(12). S320–S321.

Macaulay, R., et al.. (2020). PMU80 THE ITALIAN INNOVATION ACCELERATION? BEST PRACTICE LESSONS OF REIMBURSEMENT INCENTIVES FOR INNOVATIVE PRODUCTS. Value in Health. 23. S247–S247. 1 indexed citations

Macaulay, R. & Utsha G. Khatri. (2019). PRO111 REIMBURSEMENT OF ULTRA-ORPHAN MEDICINES: A NEW BEST-PRACTICE FRAMEWORK?. Value in Health. 22. S861–S861.

Macaulay, R., et al.. (2019). PCN196 WILL CAR-T CELL THERAPIES CHANGE HOW DRUGS ARE PRICED AND REIMBURSED?. Value in Health. 22. S92–S93. 1 indexed citations

Campbell, John, et al.. (2018). PRM38 - HOW MUCH IS YOUR LIFE WORTH? DEFINING WHAT THE WILLINGNESS TO PAY FOR A QALY IS AND SHOULD BE. Value in Health. 21. S362–S362.

Macaulay, R. & M. Hugon. (2018). Biosimilar Market Access – Comparing the US and European Markets. Value in Health. 21. S91–S91.

Macaulay, R.. (2017). Early Acess But Then What? The Uk Early Access To Medicines Scheme Three Year Report Card. Value in Health. 20(9). A661–A661. 1 indexed citations

10.

Macaulay, R., et al.. (2017). Innovative Pricing and Reimbursement Schemes – The What, Why, Which, and How. Value in Health. 20(9). A403–A404. 1 indexed citations

11.

Macaulay, R. & Pratit Patel. (2017). Applying Nice End Of Life Criteria In The ERA Of Drug Approvals Based On Single-ARM Trial Data. Value in Health. 20(9). A457–A457. 2 indexed citations

12.

Macaulay, R.. (2016). ARE THE SMC GETTING NICER? A TIME-TREND ANALYSIS OF NICE AND SMC APPRAISAL OUTCOMES. Value in Health. 19(3). A262–A262. 1 indexed citations

13.

Macaulay, R.. (2016). INDEPENDENT REVIW PANEL ASSESSMENTS: AN ALTERNATIVE ROUTE TO MARKET ACCESS IN SCOTLAND?. Value in Health. 19(3). A263–A264.

14.

Shafrin, Jason, et al.. (2016). Use of Net Monetary Benefit Analysis to Comprehensively Understand the Value of Innovative Treatments. Value in Health. 19(7). A731–A731. 9 indexed citations

15.

Macaulay, R.. (2016). The Uk Early Access To Medicines Scheme: A 2-Year Status Update On Successes, Issues And Controversies. Value in Health. 19(7). A446–A446. 1 indexed citations

16.

Macaulay, R.. (2015). Fda Breakthrough Status Versus Accelerated Approval – What’s the Difference?. Value in Health. 18(7). A522–A522. 1 indexed citations

17.

Macaulay, R.. (2014). Evidence for a Lowered Threshold for FDA Approval of Oncologics Based on Single-Arm Phase II Data, Compared to the EMA. Value in Health. 17(3). A98–A98. 1 indexed citations

18.

Macaulay, R.. (2014). Media Coverage of the Nice First Draft Consultation Guidance for Trastuzumab Emantansine (Kadcyla) In Breast Cancer. Value in Health. 17(7). A659–A659. 1 indexed citations

19.

Macaulay, R.. (2013). EMA Approval of Drugs on the Basis of Pivotal Non-Comparative Phase II Trial Data. Value in Health. 16(7). A324–A324. 1 indexed citations

20.

Berg, Pablo J. E. J. van de, Stephen Griffiths, Si‐La Yong, et al.. (2010). Cytomegalovirus Infection Reduces Telomere Length of the Circulating T Cell Pool. The Journal of Immunology. 184(7). 3417–3423. 122 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact